Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma.
Bottom Line: Expression levels of CD44/CD133 and CD204 were significantly higher in tumor tissues than in normal tissues (P < .0001).The variables associated with survival were high coexpression of CD44/CD133 (P = .000), high expression of CD204 (P = .011), and tumor grade (P = .014).Survival analysis indicated that high coexpression of CD44/CD133 and CD204 was associated significantly with shorter overall survival (P = .000) and disease-free survival (P = .003).
Affiliation: Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.Show MeSH
Related in: MedlinePlus
Mentions: TMAs sections were double stained with antibodies against the CSCs markers CD44 and CD133 or were single stained with antibody against the TAMs marker CD204. These antibodies were also used in Western blot and immunofluorescence staining to confirm CD44, CD133, or CD204 expression in cell lines (data not shown). To verify macrophages infiltration at the tumor site, those sections were also stained with antibody against the macrophages marker CD68. Different levels of CD44 and CD133 or coexpression of CD44 and CD133 (CD44/CD133) are illustrated in Figure 1A and 1B, and different expression levels of CD204 are illustrated in Figure 2A and 2B. To validate the accuracy of our data, corresponding full sections of PDAC tumors and normal tissues were stained for these markers, as displayed in Figures 1C and 2C. CD44/CD133 expression and CD204 expression were significantly higher in tumor tissues than in their normal tissue counterparts (Figs. 1D, 1E, 2D, and 2E). The mean ± standard error expression levels of CD44 (9.71% ± 0.58%), CD133 (7.31% ± 0.44%), CD44/CD133 (2.5% ± 0.18%), CD68 (22.39% ± 0.8%), and CD204 (9.18% ± 0.49%) were used to divide patients into a high-expression group and a low-expression group. In the entire pancreatic cancer cohort, 31 of 96 patients (32.3%) had high CD44/CD133 expression, and 65 of 96 patients (67.7%) had low CD44/CD133 expression; whereas 39 of 96 patients (40.6%) had high CD204 expression, and 57 of 96 patients (59.4%) had low CD204 expression (Table 1).
Affiliation: Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.